Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Posaconazole - Merck & Co

Drug Profile

Posaconazole - Merck & Co

Alternative Names: IV posaconazole; MK-5592; Noxafil; Posaconazole oral suspension; Posaconazole SP; Posaconazole tablet; Posanol; SCH 056592; SCH 56592; Spriafil

Latest Information Update: 09 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; MSD China; Schering-Plough
  • Class Antifungals; Fluorobenzenes; Furans; Ketones; Piperazines; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses; Oropharyngeal candidiasis
  • Phase II Chagas disease

Most Recent Events

  • 07 Oct 2021 Biomarkers information updated
  • 28 Jan 2021 No recent reports of development identified for phase-I development in Mycoses(Prevention) in China (IV, Infusion)
  • 19 Dec 2020 Phase-II clinical trials in Mycoses (In children, In infants) in USA (IV) (NCT04665037)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top